(-) Vical: Baird's Healthcare Conference (Vical) - Sep 12, 2013 - "Allovectin Phase 3 Results in Metastatic Melanoma"; "Failed to meet primary or secondary efficacy endpoints"; "No statistically significant improvement vs. first-line chemotherapy"; "Clear and ambiguous result"
P3 data: top line • Melanoma
|